These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38472091)

  • 1. High yield sterile filtration process for highly concentrated lentiviral vectors.
    Vogel JE; Terrao M; Schwingal S; Kapitza L; Brigulla D; Pirzas V; Laux H; Brandt T
    Biotechnol J; 2024 Mar; 19(3):e2300348. PubMed ID: 38472091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in the analysis of pharmaceutical lentiviral vector products by orthogonal and complementary physical (nano)particle characterization techniques.
    Stadler D; Helbig C; Wuchner K; Frank J; Richter K; Hawe A; Menzen T
    Eur J Pharm Biopharm; 2024 Jul; 200():114340. PubMed ID: 38797222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes.
    Yang S; Karne NK; Goff SL; Black MA; Xu H; Bischof D; Cornetta K; Rosenberg SA; Morgan RA; Feldman SA
    Hum Gene Ther Methods; 2012 Apr; 23(2):73-83. PubMed ID: 22515320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical grade lentiviral vector purification and quality control requirements.
    Shi R; Jia S; Liu H; Nie H
    J Sep Sci; 2022 Jun; 45(12):2093-2101. PubMed ID: 35247228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification.
    Segura MM; Garnier A; Durocher Y; Coelho H; Kamen A
    Biotechnol Bioeng; 2007 Nov; 98(4):789-99. PubMed ID: 17461423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application.
    Merten OW; Charrier S; Laroudie N; Fauchille S; Dugué C; Jenny C; Audit M; Zanta-Boussif MA; Chautard H; Radrizzani M; Vallanti G; Naldini L; Noguiez-Hellin P; Galy A
    Hum Gene Ther; 2011 Mar; 22(3):343-56. PubMed ID: 21043787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depth filtration for clarification of intensified lentiviral vector suspension cell culture.
    Mayani M; Nellimarla S; Mangalathillam R; Rao H; Patarroyo-White S; Ma J; Figueroa B
    Biotechnol Prog; 2024; 40(2):e3409. PubMed ID: 37985144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpikeTM Viruses.
    De Vilmorin P; Slocum A; Jaber T; Schaefer O; Ruppach H; Genest P
    PDA J Pharm Sci Technol; 2015; 69(3):440-9. PubMed ID: 26048749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Large-Scale Downstream Processing for Lentiviral Vectors.
    Valkama AJ; Oruetxebarria I; Lipponen EM; Leinonen HM; Käyhty P; Hynynen H; Turkki V; Malinen J; Miinalainen T; Heikura T; Parker NR; Ylä-Herttuala S; Lesch HP
    Mol Ther Methods Clin Dev; 2020 Jun; 17():717-730. PubMed ID: 32346549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Process intensification for lentiviral vector manufacturing using tangential flow depth filtration.
    Tona RM; Shah R; Middaugh K; Steve J; Marques J; Roszell BR; Jung C
    Mol Ther Methods Clin Dev; 2023 Jun; 29():93-107. PubMed ID: 36994313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice.
    Gándara C; Affleck V; Stoll EA
    Hum Gene Ther Methods; 2018 Feb; 29(1):1-15. PubMed ID: 29212357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing a rapid, high throughput screening platform for optimization of lentivirus production.
    Gopal S; Osborne AE; Hock L; Zemianek J; Fang K; Gee G; Ghosh R; McNally D; Cramer SM; Dordick JS
    Biotechnol J; 2021 Oct; 16(10):e2000621. PubMed ID: 34260824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Scalable Lentiviral Vector Production and Purification Method Using Mustang Q Chromatography and Tangential Flow Filtration.
    Tinch S; Szczur K; Swaney W; Reeves L; Witting SR
    Methods Mol Biol; 2019; 1937():135-153. PubMed ID: 30706394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Gene Therapy: Development and Production of Lentiviral Vectors for Gene Therapy.
    Coroadinha AS
    Methods Mol Biol; 2022; 2521():297-315. PubMed ID: 35733005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
    Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
    Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leveraging mathematical models for optimizing filter utility at manufacturing scale.
    Rose S; Dhingra A; Joseph A; Coffman J
    Biotechnol Bioeng; 2023 Jun; 120(6):1584-1591. PubMed ID: 36920041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sterile Filtration of Highly Concentrated Protein Formulations: Impact of Protein Concentration, Formulation Composition, and Filter Material.
    Allmendinger A; Mueller R; Huwyler J; Mahler HC; Fischer S
    J Pharm Sci; 2015 Oct; 104(10):3319-29. PubMed ID: 26149748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Effect of the Volume Throughput and Maximum Flux of Low-Surface-Tension Fluids on Bacterial Penetration of 0.2 Micron-Rated Filters during Process-Specific Filter Validation Testing.
    Folmsbee M
    PDA J Pharm Sci Technol; 2015; 69(2):307-16. PubMed ID: 25868996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
    Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
    J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.